Evaluation of Pre-existent Immunity in Patients with Primary Breast Cancer
Purpose: Breast cancers are known to frequently (over)express several well-characterized tumor-associated antigens (TAAs) such as carcinoembryonic antigen, MUC-1, Her-2/neu, and cancer/testis antigens such as NY-ESO-1, SSX-2, and members of the MAGE family. Whereas in melanoma patients, the detectio...
Saved in:
Published in | Clinical cancer research Vol. 9; no. 12; p. 4376 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
American Association for Cancer Research
01.10.2003
|
Online Access | Get full text |
Cover
Loading…
Summary: | Purpose: Breast cancers are known to frequently (over)express several well-characterized tumor-associated antigens (TAAs) such as
carcinoembryonic antigen, MUC-1, Her-2/neu, and cancer/testis antigens such as NY-ESO-1, SSX-2, and members of the MAGE family.
Whereas in melanoma patients, the detection of pre-existing T cell responses to tumor-associated differentiation antigens
was a rationale to initiate several vaccination strategies, little is known thus far concerning tumor-specific immunity in
breast cancer patients. The objectives of our study were ( a ) to modify and compare different immunodiagnostic T cell assays with regard to their suitability for clinical applications
and ( b ) to determine endogenous TAA-specific T cell immunity of breast cancer patients at the time point of primary diagnosis.
Experimental Design: Using MUC-1- and Her-2/neu-derived HLA-A*0201-restricted peptides as model antigens, we analyzed antigen-dependent IFN-γ
release of T cells by enzyme-linked immunospot (ELISpot) assay, intracellular cytokine flow cytometry (CytoSpot), and quantitative
real-time PCR. As an assay independent of T cell function, we performed tetramer staining.
Results: In our hands, the quantitative real-time PCR method is most sensitive and a feasible screening test to perform an “immunological
staging” of cancer patients. By doing this, we detected in 7 of 13 (54%) of HLA-A*0201 + breast cancer patients a pre-existent specific cellular immune response to at least one of the investigated TAAs (MUC-1,
Her-2/neu, carcinoembryonic antigen, NY-ESO-1, and SSX-2). Four of 21 patients (19%) were found to have a significant Her-2/neu-specific
T cell response as defined by a stimulation index ≥ 2 (range, 10–88).
Conclusions: Although the clinical relevance of endogenous TAA-specific immunity remains unclear, our findings suggest that patients with
primary breast cancer can mount a T cell immune response to their tumor that might be beneficially enhanced by TAA-dependent
vaccination strategies in the adjuvant situation. |
---|---|
ISSN: | 1078-0432 1557-3265 |